Restoring Cognition Through NLRP3 Inflammasome Inhibition


Newsletter # 139


In vivo studies


Functional validation of an inflammasome-driven cognitive impairment model

The NLRP3 inflammasome has emerged as a central driver of neuroinflammation and cognitive decline in numerous CNS and systemic inflammatory disorders, including Alzheimer's disease, Parkinson's disease, stroke, traumatic brain injury and long COVID.
EVIDENCE FOR NLRP3-DRIVEN COGNITIVE IMPAIRMENT
  • In Neurofit's LPS-induced cognitive impairment model, mice display a marked reduction in T-maze spontaneous and continuous alternation performance. Treatment with the selective NLRP3 inhibitor MCC950 produces a robust, dose-dependent restoration of cognitive function, returning performance close to healthy control levels.

CONVERGENT PHARMACOLOGICAL EVIDENCE
  • Active Compounds (Reversed Deficit)
    • N-acetylcysteine (NAC)
    • DHA (Docosahexaenoic acid)
    • Resveratrol • Ibuprofen
    • Indomethacin
    • Sulindac


    Andriambeloson et al.
    "Pharmacological Reversal of LPS-Induced Cognitive Impairments: Evidence for Inflammation-Dependent and Independent Mechanisms." Neuroscience 2025, San-Diego, USA

    Ineffective Compounds (No Significant Effect)
    • Nilotinib
    • Methylene blue
  • The cognitive deficit is also reversed by compounds known to modulate inflammatory pathways, including N-acetylcysteine (NAC), DHA, resveratrol, ibuprofen, indomethacin, and sulindac.
    In contrast, nilotinib and methylene blue failed to improve performance, demonstrating pharmacological discrimination and supporting a central role for inflammasome-driven neuroinflammation.

If you are interested in these models and would like to learn more about them or other models and assays available at NEUROFIT, please visit our website : THERAPEUTIC AREA or TESTS sections


NEUROFIT offers a range of validated in vitro and in vivo screening tests for psychiatry and neurology.

If you need further information, please do not hesitate to contact us, we will reply within few days. Custom protocol

On a regular basis we distribute newsletters with scientific information on our research services. If you wish to receive these, please :